The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Karateev D.E.

FGBU "Nauchno-issledovatel'skiĭ institut revmatologii" RAMN

Lukina G.V.

NII revmatologii RAMN, Moskva

Pharmacotherapy for rheumatoid arthritis in the early 21st century: Russian and international experience

Authors:

Nasonov E.L., Karateev D.E., Lukina G.V.

More about the authors

Journal: Therapeutic Archive. 2013;85(8): 20‑28

Read: 3209 times

Download PDF (RU)
Contact the author
Table of contents

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE EARLY 21ST CENTURY: RUSSIAN AND INTERNATIONAL EXPERIENCE
PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE EARLY 21ST CENTURY: RUSSIAN AND INTERNATIONAL EXPERIENCE

To cite this article:

Nasonov EL, Karateev DE, Lukina GV. Pharmacotherapy for rheumatoid arthritis in the early 21st century: Russian and international experience. Therapeutic Archive. 2013;85(8):20‑28. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The paper summarizes the data of international and Russian studies concerning current approaches to the pharmacotherapy of rheumatoid arthritis. Particular emphasis is placed on the substantiation of the treat-to-target concept, on the efficacy and safety of genetically engineered biological agents, including the inhibitors of tumor necrosis factor, interleukin-6 receptors, T-lymphocyte co-stimulation, and anti-B-cell therapy.

Keywords:

rheumatoid arthritis
remission
methotrexate
cytokines
tumor necrosis factor inhibitors

Authors:

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Karateev D.E.

FGBU "Nauchno-issledovatel'skiĭ institut revmatologii" RAMN

Lukina G.V.

NII revmatologii RAMN, Moskva

Close metadata

References:

  1. Nasonov E.L., Karateev D.E., Balabanova R.M. Revmatoidnyi artrit. V knige "Revmatologiya. Natsional'noe rukovodstvo". Pod red. E.L. Nasonova, V.A. Nasonovoi. M: GEOTAR-Media 2008: 290-331.
  2. Scott D.L., Wolfe F., Huizinga T.W.J. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
  3. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Pod red. E.L. Nasonova. M: IMA-PRESS 2013.
  4. Smolen J.S., Aletaha D., Bijsma J.W.J. et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.
  5. Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975.
  6. Nasonov E.L. Lechenie revmatoidnogo artrita 2012: mesto metotreksata. Nauch-prakt revmat 2012; 51 (prilozhenie): 1-24.
  7. Isaacs J.D., Cohen S.B., Emery P. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72: 329-336.
  8. Maneiro R.J., Salfado E., Carmona L., Gomez-Reino J.J. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systemic review and meta-analysis. Semin Arthritis Rheum 2013 [Epab ahead of print].
  9. Genovese M.C., Covarrubias A., Leon G. et al. Subcutaneous Abatacept versus intravenous abatacept. A phase IIIb noninferiority study in patients with an inadwquate response to methotrexate. Arthritis Rheum 2013; 63: 2854-2864.
  10. Karateev D.E., Luchikhina E.L., Murav'ev Yu.V. i dr. Pervoe Rossiiskoe strategicheskoe issledovanie farmakoterapii revmatoidnogo artrita (REMARKA). Nauch-prakt revmatol 2013; 2: 117-125.
  11. Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
  12. Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010; 10: 308-315.
  13. Karateev D.E., Nasonov E.L., Luchikhina E.L. i dr. Effektivnost' i bezopasnost' lecheniya adalimumabom bol'nykh aktivnym revmatoidnym artritom s rezistentnost'yu k standartnoi terapii: rezul'taty Rossiiskogo natsional'nogo issledovaniya. Ter arkh 2012; 8: 22-28.
  14. Smolen J.S., Nash P., Durez P. et al. Maintenance, reduction or withdrawal of Etanercept: a randomized controlled trial in moderate rheumatoid arthritis patients achieving low disease activity with etanercept-methotrexate therapy. Lancet 2013; 381: (91): 918-929.
  15. Pavelka K., Szekanecz Z., Damjanov N. et al. Induction of response with etanercept-methotrexate therapy in patients with moderate active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study Clinical Rheumatology (Accepted to publication).
  16. Karateev D.E., Nasonov E.L., Denisov L.N. i dr. Novye vozmozhnosti terapii revmatoidnogo artrita: rossiiskii opyt primeneniya tsertolizumaaba pegol. Nauch-prakt revmatol 2011; 2: 104-110.
  17. Panasyuk E.Yu., Amirdzhanova V.N., Avdeeva F.S. i dr. Opyt primeneniya totsilizumaba u bol'nykh revmatoidnym artritom (po dannym mnogotsentrovogo issledovaniya LORNET). Nauch-prakt revmatol 2013; 2: 104-110.
  18. Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-1580.
  19. Chatzidionysiou K., Lie E., Nasonov E. et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in Rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012; 71: 374-377.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.